Pharmacology · Opioid Pharmacology

Opioid Receptors and the Endogenous Opioid System

Receptor types, signal transduction, endogenous peptides, and tolerance

All three classical opioid receptors (mu, kappa, delta) are GPCRs that couple to inhibitory Gi/Go proteins — their shared mechanism is inhibition of neuronal excitability, but their distribution and circuits determine distinct pharmacological profiles.
The mu receptor drives virtually all clinically relevant opioid pharmacology: supraspinal and spinal analgesia, euphoria, respiratory depression, constipation, miosis, and physical dependence are all primarily mu-mediated effects.
Three downstream effects of Gi/Go coupling work in concert — inhibition of adenylyl cyclase, opening of K⁺ channels, and closure of Ca²⁺ channels — producing the same reduced neuronal excitability that silences pain circuits and depresses brainstem respiratory centers.
Tolerance develops to analgesia, euphoria, sedation, nausea, and respiratory depression — but not to constipation or miosis; patients on long-term opioids retain pinpoint pupils and persistent constipation regardless of duration of therapy.
Physical dependence (neuroadaptation with withdrawal on cessation) is mechanistically distinct from addiction (compulsive use despite harm via mesolimbic dopamine circuits) — the two concepts are often conflated but require separate clinical consideration.

The Three Classical Opioid Receptors

Mu Receptor

Primary Clinical Target

Supraspinal and spinal analgesia
Euphoria / reward
Respiratory depression
Constipation (peripheral)
Miosis
Physical dependence

Kappa Receptor

Mixed Agonist Target

Spinal analgesia
Sedation
Dysphoria
Miosis
Target of buprenorphine, nalbuphine, butorphanol

Delta Receptor

Mood and Analgesia

Supraspinal and spinal analgesia
Mood modulation
Enhances mu receptor signaling
No approved selective agonist

Gi/Go Signal Transduction: Three Downstream Effects

Agonist Binds Receptor

Gi/Go protein activated

→

Effect 1

Inhibit adenylyl cyclase
cyclic AMP decreases

Effect 2

Open K⁺ channels
hyperpolarization

Effect 3

Close Ca²⁺ channels
less neurotransmitter release

→

Net Result

Reduced neuronal excitability
Analgesia

Endogenous Opioid Peptide Families

Peptide Family	Precursor Protein	Receptor Preference	Key Physiological Role
Beta-endorphin	Pro-opiomelanocortin	Mu, delta	Stress-induced analgesia; exercise-related mood elevation
Enkephalins	Proenkephalin	Delta, mu	Spinal dorsal horn pain modulation; short-range neurotransmitter
Dynorphins	Prodynorphin	Kappa	Stress response; dysphoria in limbic circuits

Tolerance, Dependence, and Addiction: Key Distinctions

Concept

Tolerance

Reduced response at same dose
Develops to: analgesia, euphoria, sedation, respiratory depression, nausea
Does NOT develop to constipation or miosis

Concept

Physical Dependence

Neuroadaptation requiring opioid for normal function
Withdrawal on abrupt cessation
Mechanism: cyclic AMP rebound from upregulated adenylyl cyclase
Does NOT equal addiction

Concept

Addiction (Opioid Use Disorder)

Compulsive use despite harm
Mesolimbic dopamine pathway (ventral tegmental area to nucleus accumbens)
Faster delivery = greater reward signal
Distinct from dependence

Clinical Rule: What Tolerizes and What Does Not

Tolerance develops to analgesia, euphoria, sedation, nausea, and respiratory depression. Tolerance does not develop to constipation or miosis. A patient on long-term opioid therapy will retain pinpoint pupils and persistent constipation regardless of how long they have been on the medication.

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed. Chapter 31: Opioid Analgesics and Antagonists	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 20: Opioids, Analgesia, and Pain Management	McGraw-Hill, 2023
Pasternak GW, Pan YX	Mu opioids and their receptors: evolution of a concept	Pharmacol Rev. 2013;65(4):1257–1317
Brownstein MJ	A brief history of opiates, opioid peptides, and opioid receptors	Proc Natl Acad Sci USA. 1993;90(12):5391–5393
Hughes J, Smith TW, Kosterlitz HW, et al	Identification of two related pentapeptides from the brain with potent opiate agonist activity	Nature. 1975;258(5536):577–580
Williams JT, Ingram SL, Henderson G, et al	Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance	Pharmacol Rev. 2013;65(1):223–254
Stein C	Opioid receptors	Annu Rev Med. 2016;67:433–451
Koob GF, Volkow ND	Neurobiology of addiction: a neurocircuitry analysis	Lancet Psychiatry. 2016;3(8):760–773
Pattinson KT	Opioids and the control of respiration	Br J Anaesth. 2008;100(6):747–758
Corbett AD, Henderson G, McKnight AT, Paterson SJ	75 years of opioid research: the exciting but vain quest for the Holy Grail	Br J Pharmacol. 2006;147(Suppl 1):S153–S162